Polymorphonuclear Cells' Sensitivity to Aggregatibacter Actinomycetemcomitans Bacteria in Patients With Aggressive Periodontitis

NCT ID: NCT02010307

Last Updated: 2013-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

aggressive periodontitis is an inflammatory disease which damage the teeth supporting structures mostly in young patients. and has genetic basis.

a specific bacteria: Aggregatibacter actinomycetemcomitans (Aa) is associated with this disease, and found to damage leukocytes by using a specific leukotoxin.

in the research the investigators are aiming to find molecular and immunological basis to aggressive periodontitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

aggressive periodontitis

25 patients with aggressive periodontitis blood extraction

Group Type EXPERIMENTAL

blood extraction

Intervention Type OTHER

6 ml blood extraction from each patients in all 3 arms of the study

chronic periodontitis

25 patients with chronic periodontitis blood extraction

Group Type EXPERIMENTAL

blood extraction

Intervention Type OTHER

6 ml blood extraction from each patients in all 3 arms of the study

healthy

25 healthy periodontal patients blood extraction

Group Type EXPERIMENTAL

blood extraction

Intervention Type OTHER

6 ml blood extraction from each patients in all 3 arms of the study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood extraction

6 ml blood extraction from each patients in all 3 arms of the study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients in periodontal department
* healthy
* diagnosed with chronic/aggressive periodontal disease
* interested in participating the research

Exclusion Criteria

* diagnosed with diabetes, heart disease, immunosuppression, thrombocytopenia, clotting enzyme deficiency.
* using alcohol, or drugs
* pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Polak David

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Polak David

senior dentist, periodontology department

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Polak, DMD, PhD

Role: PRINCIPAL_INVESTIGATOR

Haddasah Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hadassah Medical Organization, Jerusalem, Israel

Jerusalem, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

David Polak, DMD, PhD

Role: CONTACT

Phone: 00972- 52-593-3961

Email: [email protected]

Hadas Lemberg, PhD

Role: CONTACT

Phone: 00-972-2-6777572

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

davidp-HMO-CTIL

Identifier Type: -

Identifier Source: org_study_id